Scientists have discovered a new way to boost the immune system
Immunotherapy is a type of cancer treatment that harnesses the body's natural immune defense system to attack tumor cells. While there has been a lot of focus on getting T cells involved in fighting cancer, there has been less focus on directing the complement system to the tumor. The complement system is an important part of the innate immune system, helping to fight infections, heal damage and clear away dead cells. Although antibodies (proteins produced by immune cells) can activate the complement system, not all antibodies activate the complement system equally effectively.
The researchers developed a method using bispecific single-domain antibodies, known as BiCEs, which activate the complement system to target and kill cancer cells more effectively than current methods. This innovative approach can mobilize more immune responses in the body, thus revolutionizing cancer immunotherapy, and has clinical application potential.
In the new study, the researchers developed a way to activate the complement system using bispecific single-domain antibodies, called BiCEs. These antibodies can bind to two different targets simultaneously: a complement protein called C1q and a specific protein that exists on the surface of cancer cells.
By linking C1q and cancer cell proteins, the BiCE molecule strongly activates the complement system to specifically kill the target cancer cell.
Researchers at Commit Biologics, Kiel Christian-Albrechts University and Aarhus University have discovered a new way to boost the immune system. From left, Stephen Thiel, Annette G. Hansen, Dennis V. Pedersen, Nick S. Laursen, Heidi Gytz Olesen, Gregers R. Andersen, and Mikael B. L. Winkler. Source: Lisbeth Heilesen, Aarhus University
Compared to antibodies currently in clinical use, BiCE molecules are superior in activating the complement system and killing cancer cells. This new approach has several advantages over traditional cancer therapies, one of which is the potential to activate a broader immune response by harnessing the power of the innate immune system, including recruiting immune cells into the tumor microenvironment to enhance anti-tumor activity.
The findings not only highlight the innovative research carried out at Aarhus University, but also pave the way for further advances in the field of cancer immunotherapy. Going forward, the spin-off enterprise resulting from this collaboration aims to translate research findings into clinical applications.
Scientists have discovered a new way to boost the immune system
Immunotherapy is a type of cancer treatment that harnesses the body's natural immune defense system to attack tumor cells. While there has been a lot of focus on getting T cells involved in fighting cancer, there has been less focus on directing the complement system to the tumor. The complement system is an important part of the innate immune system, helping to fight infections, heal damage and clear away dead cells. Although antibodies (proteins produced by immune cells) can activate the complement system, not all antibodies activate the complement system equally effectively.
The researchers developed a method using bispecific single-domain antibodies, known as BiCEs, which activate the complement system to target and kill cancer cells more effectively than current methods. This innovative approach can mobilize more immune responses in the body, thus revolutionizing cancer immunotherapy, and has clinical application potential.
In the new study, the researchers developed a way to activate the complement system using bispecific single-domain antibodies, called BiCEs. These antibodies can bind to two different targets simultaneously: a complement protein called C1q and a specific protein that exists on the surface of cancer cells.
By linking C1q and cancer cell proteins, the BiCE molecule strongly activates the complement system to specifically kill the target cancer cell.
Researchers at Commit Biologics, Kiel Christian-Albrechts University and Aarhus University have discovered a new way to boost the immune system. From left, Stephen Thiel, Annette G. Hansen, Dennis V. Pedersen, Nick S. Laursen, Heidi Gytz Olesen, Gregers R. Andersen, and Mikael B. L. Winkler. Source: Lisbeth Heilesen, Aarhus University
Compared to antibodies currently in clinical use, BiCE molecules are superior in activating the complement system and killing cancer cells. This new approach has several advantages over traditional cancer therapies, one of which is the potential to activate a broader immune response by harnessing the power of the innate immune system, including recruiting immune cells into the tumor microenvironment to enhance anti-tumor activity.
The findings not only highlight the innovative research carried out at Aarhus University, but also pave the way for further advances in the field of cancer immunotherapy. Going forward, the spin-off enterprise resulting from this collaboration aims to translate research findings into clinical applications.
To be or not to be, this is a question.
To be or not to be, this is a question.
Share Dialog
Share Dialog
Subscribe to EricTTT
Subscribe to EricTTT
<100 subscribers
<100 subscribers
No activity yet